An interventional study of Diabetes Self-Management and Support (DSMES) and Sleep Hygiene Education and Support (SHES) in Diabetes Mellitus, Type 2 and Sleep Hygiene, sponsored by University of Arkansas. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-03.
Sponsored by University of Arkansas · Not applicable, Interventional, and Prevention
This study will test whether adding sleep hygiene education and support to diabetes self-management education and support (DSMES) in diverse patients (African American, Hispanic, Pacific Islander, and Caucasian) with type 2 diabetes myelitis (T2DM) from rural UAMS Regional Programs clinics is more effective than DSMES alone. The specific aims for this study are:
9,589 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,332 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →University of Arkansas is the lead sponsor of 398 studies on the registry; 37 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 34 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Behavioral: Diabetes Self-Management and Support (DSMES) and Sleep Hygiene Education and Support (SHES)
SHES outlines the importance of sleep for people with type 2 diabetes mellitus and provide practical information and guidance about sleep habits. Specifically, the focus will be on: avoiding consumption of caffeine, nicotine, alcohol; avoiding use of light emitting devices before bedtime; avoiding excessive intake of fluids or heavy meals before bedtime; promoting regulation of light, noise, and temperature in the bedroom; timing of and importance of exercise; maintaining consistent sleep and wake times; establishing a pre-bedtime routine; and managing stress.
Change in mean HbA1c (NGSP%) from baseline to 12 weeks post-intervention
A Siemens analyzer will be utilized to calculate HbA1c (%) for each participant at each time point. Changes in the primary outcome measure will be assessed from baseline to post-intervention.
Time frame: Baseline and 12 weeks post-intervention
Change in sleep duration from baseline to 12 weeks post-intervention
Self-reported sleep duration (hours slept) will be assessed using valid Behavioral Risk Factor Surveillance System survey items.
Time frame: Baseline and 12 weeks post-intervention
Change in sleep quality from baseline to 12 weeks post-intervention
The PROMIS® Short Form v1.0- Sleep Disturbance-4a scale will be used to assess self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep.This includes perceived difficulties and concerns with getting to sleep or staying asleep, as well as perceptions of the adequacy of and satisfaction with sleep.
Time frame: Baseline and 12 weeks post-intervention
Change in mean blood pressure (systolic & diastolic, mmHg) from baseline to 12 weeks post-intervention
Blood pressure will be measured with a sphygmomanometer and stethoscope or digital blood pressure device with the participant seated and arm elevated.
Time frame: Baseline and 12 weeks post-intervention
Change in mean body mass index (BMI) from baseline to 12 weeks post-intervention
BMI will be collected by measuring participant height (without shoes) using a stadiometer, and by measuring participant weight (without shoes) using a calibrated digital scale. Participant weight and height will then be used to compute a continuous measure of BMI.
Time frame: Baseline and 12 weeks post-intervention
Change in mean total cholesterol (mg/dL) from baseline to 12 weeks post-intervention
Through finger prick blood collection, point of care tests will be used used to test total cholesterol using a commercial lipid panel kit and Cholestech LDX analyzer.
Time frame: Baseline and 12 weeks post-intervention
Change in mean low-density lipoproteins (LDL) (mg/dL) from baseline to 12 weeks post-intervention
Through finger prick blood collection, point of care tests will be used used to test LDL using a commercial lipid panel kit and Cholestech LDX analyzer.
Time frame: Baseline and 12 weeks post-intervention
Change in mean high-density lipoproteins (HDL) (mg/dL) from baseline to 12 weeks post-intervention
Through finger prick blood collection, point of care tests will be used used to test HDL using a commercial lipid panel kit and Cholestech LDX analyzer.
Time frame: Baseline and 12 weeks post-intervention
Change in mean triglycerides (mg/dL) from baseline to 12 weeks post-intervention
Through finger prick blood collection, point of care tests will be used used to test triglycerides using a commercial lipid panel kit and Cholestech LDX analyzer.
Time frame: Baseline and 12 weeks post-intervention
Change in diabetes self-management behaviors from baseline to 12 weeks post-intervention
The Summary of Diabetes Self-Care Activities (SDSCA) will be used to measure engagement in self-management activities. The SDSCA consists of 12 items to assess the self-reported frequency of performing diabetes self-care tasks, including testing blood sugar, following healthful eating plans, and exercising regularly.
Time frame: Baseline and 12 weeks post-intervention
Change in diabetes-related self-efficacy from baseline to 12 weeks post-intervention
The Diabetes Management Self-Efficacy Scale (DMSES) will be used to measure patient's confidence in managing their diabetes. The DMSES consists of 8 items to assess self-reported confidence in managing aspects of their diabetes. Items are scored on a 0-10 point scale, with higher scores indicating higher levels of self-efficacy.
Time frame: Baseline and 12 weeks post-intervention
Change in diabetes-related distress from baseline to 12 weeks post-intervention
The Problem Areas in Diabetes Scale (PAID)-5 will be used to measure diabetes distress. The PAID-5 consists of 5 items to assess self-reported diabetes-related emotional distress, including feeling scared or depressed. Items are scored on a 0-4 point scale, with higher scores indicating higher levels of distress.
Time frame: Baseline and 12 weeks post-intervention
Change in diabetes-related quality of life from baseline to 12 weeks post-intervention
The DAWN2 Impact of Diabetes Profile (DIDP) will be used to measure the perceived impact of diabetes on patients' quality of life. The DIDP consists of 6 items to assess self-reported impacts on quality of life, including physical health, financial situation, and relationships with others.
Time frame: Baseline and 12 weeks post-intervention
Plan to share: No
No publications or documents are linked to this record.
This study is withdrawn, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.